Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIO-1: Eganelisib +/- Nivolumab in Advanced Solid Tumors
NCT02637531Phase 1Unknown
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Dec 2015
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eganelisib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), melanoma and 4 more (8 arms), sponsored by Infinity Pharmaceuticals, Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 100 days. Status: unknown.
02
Drugs
eganelisib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)melanomasquamous cell carcinoma of the head and neck (HNSCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02637531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637531.